Literature DB >> 28471659

Urinary Tract Infection: Which Conformation of the Bacterial Lectin FimH Is Therapeutically Relevant?

Katharina Mayer1, Deniz Eris1, Oliver Schwardt1, Christoph P Sager1, Said Rabbani1, Simon Kleeb1, Beat Ernst1.   

Abstract

Frequent antibiotic treatment of urinary tract infections has resulted in the emergence of antimicrobial resistance, necessitating alternative treatment options. One such approach centers around FimH antagonists that block the bacterial adhesin FimH, which would otherwise mediate binding of uropathogenic Escherichia coli to the host urothelium to trigger the infection. Although the FimH lectin can adopt three distinct conformations, the evaluation of FimH antagonists has mainly been performed with a truncated construct of FimH locked in one particular conformation. For a successful therapeutic application, however, FimH antagonists should be efficacious against all physiologically relevant conformations. Therefore, FimH constructs with the capacity to adopt various conformations were applied. By examining the binding properties of a series of FimH antagonists in terms of binding affinity and thermodynamics, we demonstrate that depending on the FimH construct, affinities may be overestimated by a constant factor of 2 orders of magnitude. In addition, we report several antagonists with excellent affinities for all FimH conformations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28471659     DOI: 10.1021/acs.jmedchem.7b00342

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Conformational switch of the bacterial adhesin FimH in the absence of the regulatory domain: Engineering a minimalistic allosteric system.

Authors:  Said Rabbani; Brigitte Fiege; Deniz Eris; Marleen Silbermann; Roman Peter Jakob; Giulio Navarra; Timm Maier; Beat Ernst
Journal:  J Biol Chem       Date:  2017-11-27       Impact factor: 5.157

Review 2.  Therapeutic Approaches Targeting the Assembly and Function of Chaperone-Usher Pili.

Authors:  John J Psonis; David G Thanassi
Journal:  EcoSal Plus       Date:  2019-03

3.  RMSD analysis of structures of the bacterial protein FimH identifies five conformations of its lectin domain.

Authors:  Pearl Magala; Rachel E Klevit; Wendy E Thomas; Evgeni V Sokurenko; Ronald E Stenkamp
Journal:  Proteins       Date:  2019-11-05

Review 4.  What contributes to an effective mannose recognition domain?

Authors:  Christoph P Sager; Deniz Eriş; Martin Smieško; Rachel Hevey; Beat Ernst
Journal:  Beilstein J Org Chem       Date:  2017-12-04       Impact factor: 2.883

5.  Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection.

Authors:  Vasilios Kalas; Michael E Hibbing; Amarendar Reddy Maddirala; Ryan Chugani; Jerome S Pinkner; Laurel K Mydock-McGrane; Matt S Conover; James W Janetka; Scott J Hultgren
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

Review 6.  Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections.

Authors:  Matthew B Calvert; Varsha R Jumde; Alexander Titz
Journal:  Beilstein J Org Chem       Date:  2018-10-11       Impact factor: 2.883

7.  Surface modulation of single-walled carbon nanotubes for selective bacterial cell agglutination.

Authors:  Elena Romero-Ben; Juan José Cid; Mohyeddin Assali; Elisabeth Fernández-García; Ralf Erik Wellinger; Noureddine Khiar
Journal:  Int J Nanomedicine       Date:  2019-05-10

Review 8.  Recent Advances in the Control of Clinically Important Biofilms.

Authors:  Katarzyna Krukiewicz; Alicja Kazek-Kęsik; Monika Brzychczy-Włoch; Marek J Łos; Collins Njie Ateba; Parvaneh Mehrbod; Saeid Ghavami; Divine Yufetar Shyntum
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

Review 9.  Developments in Mannose-Based Treatments for Uropathogenic Escherichia coli-Induced Urinary Tract Infections.

Authors:  Natasha E Hatton; Christoph G Baumann; Martin A Fascione
Journal:  Chembiochem       Date:  2020-11-02       Impact factor: 3.164

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.